Work

EGFR T790M mutation testing within the osimertinib AURA Phase I study

Year: 2017

Type: article

Source: Lung Cancer

DOI: 10.1016/j.lungcan.2017.04.011

Authors: Simon Dearden, Helen Brown, Suzanne Jenkins, Kenneth S. Thress, Mireille Cantarini, Rebecca Cole, Malcolm Ranson, Pasi A. Jänne

Institutions: AstraZeneca (United Kingdom), AstraZeneca (United States), The Christie Hospital, The Christie NHS Foundation Trust, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2606085598

FWCI: 3.651

Cites: 32

Cited by: 26

Related to: 10